U.S. Markets close in 5 hrs 57 mins

Blog Exposure - FDA Approves First Automated Robotic Movement in technIQ(TM) Series for Corindus’ CorPath GRX Platform

Stock Monitor: Apollo Endosurgery Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 07, 2018 / Active-Investors.com has just released a free research report on Corindus Vascular Robotics, Inc. (NYSE: CVRS) ("Corindus"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CVRS as the Company's latest news hit the wire. On March 05, 2018, the Company announced that the US Food and Drug Administration (FDA) has approved the first automated robotic movement designed for its CorPath GRX platform in peripheral vascular interventions. The proprietary software feature, named "Rotate on Retract" (RoR), is the first automated robotic movement in the technIQ Series for the CorPath GRX platform. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Apollo Endosurgery, Inc. (NASDAQ: APEN), which also belongs to the Healthcare sector as the Company Corindus Vascular Robotics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=APEN

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Corindus Vascular Robotics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CVRS

About ‘Rotate on Retract' Feature

RoR allows the operator to quickly navigate to a targeted lesion by automatically rotating the guidewire upon joystick retraction. Pre-clinical data presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in October 2017 demonstrated a significant reduction in wiring time among a highly-experienced group of physicians, when comparing robotic wiring versus robotic wiring with RoR-enabled. Following the software's CE Mark approval in January 2018, the first percutaneous coronary interventional procedures were performed in the world using RoR. A robotic-assisted peripheral intervention utilizing RoR will be performed.

The Automation Software Can Extend Clinical Capabilities of CorPath GRX in More Complex Procedures

J. Aaron Grantham, M.D., Chief Medical Officer of Corindus, stated that this first-of-its-kind automation software has the potential to extend the clinical capabilities of CorPath GRX in more complex procedures. He added that bringing consistency to interventional procedures through advanced wire movements has the opportunity to reduce procedure time and enhance patient outcomes.

FDA Clearance of the Software Feature Marks First Step on Corindus' Path to Full Autonomous Navigation

Mark Toland, President and Chief Executive Officer (CEO) of Corindus, mentioned that the FDA clearance of this new software feature marks the first step on the Company's path to full autonomous navigation. Over the next several years, Corindus will focus on automating the techniques of world-class physicians to make them available to every hospital with a vascular robotic program. Toland added that the Company believes that artificial intelligence through procedural automation will increase the value of robotics in the cath lab by reducing variability of treatment and procedure time, and improving the overall quality of patient care.

Corindus Received FDA Clearance for CorPath GRX System in PVI Procedure

On February 20, 2018, the Company received a 510(k) clearance from the FDA for use of its CorPath GRX System in peripheral vascular interventions. The CorPath System is the first and only FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) procedures.

About CorPath GRX Platform

Corindus developed CorPath GRX, a second generation robotic-assisted PCI system, to support the delivery and manipulation of guidewires and catheters. The physician manipulates the devices via a control panel that displays what is going on inside the patient using angiographic fluoroscopy. CorPath GRX helps to position stents exactly where needed with 1mm movement.

About Corindus Vascular Robotics, Inc.

Founded in 2002 and headquartered in Waltham, Massachusetts, Corindus is a global technology leader in robotic-assisted percutaneous coronary interventions. The Company's CorPath System brings robotic-assisted precision to percutaneous coronary interventions.

Stock Performance Snapshot

March 06, 2018 - At Tuesday's closing bell, Corindus Vascular Robotics' stock rose 4.31%, ending the trading session at $1.21.

Volume traded for the day: 1.12 million shares, which was above the 3-month average volume of 659.49 thousand shares.

Stock performance in the last month – up 15.24%; past twelve-month period – up 1.68%; and year-to-date - up 19.80%

After yesterday's close, Corindus Vascular Robotics' market cap was at $219.64 million.

The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors